Risperidone therapy in the control of behavioural disturbances in patients with learning disability

Irish Journal of Psychological Medicine

Volumn 14, Issue 2, 1997, Pages 69-71

  Natarajan, Dhanapal ^a   Martin, Alberto Jarabo ^b   Tesh, Dorothy ^b  

^a Grounds of St Cadoc's Hospital   (United Kingdom)

^b Lea Castle Centre   (United Kingdom)

Author keywords

Behavioural disturbances; Learning disability; Risperidone

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; RISPERIDONE;

ARTICLE; BEHAVIOR; BEHAVIOR DISORDER; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HUMAN; LEARNING DISORDER;

EID: 0030876121     PISSN: 07909667     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0790966700003050     Document Type: Article

References (18)

1. Roose K, Gelders YG, Heylen SLE. Risperidone (R64766) in psychotic patients. A first clinical therapeutic exploration. Acta Psychiatr Belg 1988; 88: 233-41.
2. Mesotten E, Suy E, Pietquin M, Burton P, Heylen SLE, Gelders YG. Therapeutic effect and safety of increasing doses of risperidone (R64766) in psychotic patients. Psychopharmacology 1988; 89: 445-9.
3. Gelders YG. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br J Psychiatry 1989; 155(5): 33-6.
4. Meco G, Bedini L, Bonifati V, Sonsini U. Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia: a single-blind crossover study versus placebo. Curr Ther Res 1989; 46: 876-83.
5. Gelders YG, Heylen SLE, Vanden Bussche G, Reyntjens AJM, Janssen PAJ. Risperidone (R64766) in the treatment of psychotic patients: an open dose finding study. Pharma-copsychiatry 1990; 23: 206-11.
6. Castelao JF, Ferreira L, Gelders YG, Heylen SLE. The efficacy of the D2 and 5-HT2 antagonist risperidone (R64766) in the treatment of chronic psychosis. An open dose finding study. Schizophrenic Res 1989; 2: 411-5.
7. Bersani G, Bressa GM, Meco G, Arini S, Pozzi F. Combined serotonin 5-HT2 and dopamine-D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R64766). Hum Psychopharmacol 1990; 5; 225-31.
8. Claus A, Bollen J, DeCuyper H et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992; 85: 295-305.
9. Elaine Catherine Wright. The presentation of mental illness in mentally retarded adults. Br J Psychiatry 1982; 141: 496-502.
10. Reid AH. Diagnosis of psychiatric disorder in the severely and profoundly retarded patient. Jr Royal Soc Med 1980; 73(September).
11. Kirman BH. Mental illness and mental handicap: Reflections on diagnostic problems and prevalence. In: James FE and Smith RP eds. Psychiatric illness and mental handicap. Ashford, Kent: Headley Brothers.
12. DeCuyper H, Van Praag HM, Verstraeten D. The effects of milenperone on the aggressive behaviour of oligo-phrenic patients. A double-blind placebo controlled trial. Neuropsychobiology 1985; 13: 101-5.
13. Murti Rao J, Cowie VA, Mathew B. Tardive dyskinesia in neuroleptic medicated mentally handicapped subjects. Acta psychiatric scand 1987; 76: 507-13.
14. Murti Rao J, Cowie VA, Mathew B. Neuroleptic induced parkinsonian side effects in the mentally handicapped 1989; 33: 81-6.
15. Van Hemert JCJ. Pipamperone (Dipiperon) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long term follow up. Acta Psychiatr Scand 1975; 52: 237-45.
16. Deberdt R. Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large scale multicentre evaluation. Acta Psychiatr Belg 1976; 76: 157-66.
17. Haegeman J, Duyek F. A retrospective evaluation of pipamperone (Dipiperon) in the treatment of behavioural deviations in severely mentally handicapped. Acta Psychiatr Belg 1978; 78: 392-98.
18. Vanden Borre R, Vermote R, Buttiens M et al. Risperidone as add-on therapy in behavioural disturbances in mental retardation: a double-blind placebo controlled cross-over study. Acta Psychiatr Scand 1993; 87: 167-71.